Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Acadia Pharmaceutica (NQ: ACAD )

16.54 +0.17 (+1.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks. 
Via MarketBeat
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
Via Benzinga
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
What's Going On With ACADIA Pharmaceuticals Stock?
ACADIA Pharmaceuticals shares are trading lower by 4.6% during Tuesday's session. The company appointed Catherine Owen Adams as CEO. 
Via Benzinga
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic. 
Via Benzinga
Ryan Reynolds Announces More to Parkinson’s® Campaign
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
From Acadia Pharmaceuticals, Inc.
Via Business Wire
3 Sorry Pharma Stocks to Sell in May While You Still Can
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Exposures Information Security
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.